Esketamine Hydrochloride

MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it is set to join the broad-market Russell 3000 ® Index and the small-cap Russell 2000 ® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. The broad-market Russell 3000 ® Index includes the largest 3,000 U.S. public companies by market capitalization. The Russell 2000® Index is a subset of the broader Russell 3000® Index limited to small-cap companies. The indexes are reconstituted annually by re-ranking companies based on total market capitalization as of the reconstitution rank date, which was April 30, 2025 this year. Index membership remains in place for one year and results in automatic inclusion in the relevant growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. "This inclusion in the Russell 3000® and Russell 2000® Indexes represents an important validation of our strategic vision and operational execution," said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. "As we continue expanding access to innovative mental health treatments through our integrated approach—combining our leading NeuroStar technology with our growing Greenbrook clinic network—this milestone enhances our visibility among institutional investors and reflects the significant progress we've made in transforming how mental healthcare is delivered. With our path to positive cash flow this year and our proven operating model driving strong growth, we're well-positioned to continue delivering value for both patients and shareholders." About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.4 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) CIII Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression. The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com. “Safe harbor” statement under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release, including the documents incorporated by reference herein, include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our ability to successfully complete the announced restructuring plans; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; our revenue has been concentrated among a small number of customers; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; the terms of our credit facility; our ability to successfully roll-out our Better Me Provider Program on the planned timeline; our self-sustainability and existing cash balances; and our ability to achieve cash flow breakeven in the third quarter of 2025. For a discussion of these and other related risks, please refer to the Company’s recent filings with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations. Investor Contact: Mike Vallie or Mark Klausner ICR Healthcare 443-213-0499 ir@neuronetics.com Media Contact: EvolveMKD 646-517-4220 NeuroStar@evolvemkd.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

On Day 29, when both cohorts had received a 15 mg dose, 55% of people in the low-dose cohort and 94% in the high-dose arm achieved remission.\n Almost all the patients with depression who received Gilgamesh Pharmaceuticals’ psychedelic drug candidate went into remission, furthering the biotech’s attempt to follow the trail blazed by Johnson & Johnson.Gilgamesh\'s phase 2a trial enrolled 40 people with major depressive disorder (MDD) to test GM-2505, an agonist of the 5-HT2A receptor that is central to the psychedelic response to drugs such as LSD and psilocybin. Gilgamesh designed GM-2505 to be shorter acting than psilocybin, opening the door to its use under the two-hour in-clinic framework that J&J established for its ketamine drug Spravato.Half the patients received 10 mg of GM-2505 on Day 1 and 15 mg of the drug candidate on Day 15. The other 50% of patients began with a low-dose psychoactive comparator of 1 mg before receiving a 15 mg dose on Day 15. Scores on the Montgomery-Åsberg Depression Rating Scale (MADRS) at baseline were 31.9 and 33.4 in the low and high-dose arms, respectively.By Day 14, MADRS scores in the high-dose arm had fallen 21.6 points and 70% of patients were in remission. The mean change on the low dose was 12.1 points, with 25% of patients in remission. On Day 29, when both cohorts had received a 15 mg dose, 55% of people in the low-dose cohort and 94% of those in the high-dose arm were in remission.Day 29 MADRS scores were down 21.1 and 28 points, respectively, in the low- and high-dose cohorts. After 74 days, the scores were still down 19.7 and 25.1 points, respectively, in the low- and high-dose cohorts. Gilgamesh included 17 patients in the high-dose analyses at Day 29 and 74, down from the 20 people who completed the Day 14 assessment. The biotech reported no serious adverse events. Mass General Brigham’s Maurizio Fava, M.D., said in Gilgamesh’s statement that the phase 2a data “are impressive, in particular the large and sustained remission rates.” Fava added that “the robust effect size is compelling given the use of a truly psychoactive comparator in this study.”J&J linked (PDF) Spravato to a 19.8-point reduction on MADRS from a baseline of 37 points at Week 4 of its phase 3 trial. Almost 53% of patients were in remission. Meanwhile, Compass Pathways linked its psilocybin drug candidate to MADRS reductions of up to 12 points, from a baseline of 32 or 33, at Week 3 of its phase 2 trial. Cross-trial comparisons can be unreliable, but the available data suggest GM-2505 is competitive. An earlier study found GM-2505 causes altered states of consciousness and other effects associated with the administration of a psychedelic. The 45-minute half-life of GM-2505 differentiates the molecule from psilocybin and could make the treatment easier to incorporate into clinical practice. Fierce Biotech\'s Fierce 15 2024 winner Gilgamesh raised $39 million in 2022 and pocketed $65 million from AbbVie last year in a pact designed to develop next-gen psychiatric therapies.